Comparative Pharmacology
Head-to-head clinical analysis: TRAVASOL 2 75 IN DEXTROSE 5 IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVASOL 2 75 IN DEXTROSE 5 IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER.
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER vs TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis and energy metabolism; dextrose provides caloric support.
TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.
Intravenous infusion. Typical adult dose: 500 mL to 1000 mL per day administered at a rate not exceeding 5 mL/kg/hour, based on protein and electrolyte requirements.
Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.
None Documented
None Documented
Not applicable; components are endogenous substances with rapid metabolic turnover. Exogenous amino acids have half-lives of minutes to hours, dextrose ~1-2 hours.
Not applicable as TRAVASOL 4.25% IN DEXTROSE 25% is a nutrient solution, not a drug with a defined elimination half-life.
Renal: 100% of infused amino acids and dextrose are metabolized or excreted; no intact drug excretion. Biliary/fecal: negligible.
The amino acids and dextrose are completely metabolized; no significant renal or biliary excretion of intact product.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution